Today: 21 July 2026
Figma stock price jumps 10% as battered software names rebound ahead of earnings
10 February 2026
1 min read

Figma stock price jumps 10% as battered software names rebound ahead of earnings

New York, Feb 10, 2026, 10:39 EST — Regular session

  • Figma shares climbed roughly 10% early in New York, rebounding after a steep selloff across the sector.
  • Dip buyers jumped back in, driving retail inflows to a record high for a key tech-software ETF.
  • FIG’s next shot at moving the needle comes with its earnings report on Feb. 18.

Shares of Figma, Inc. (FIG) climbed 10.4% to $24.41 by about 10:40 a.m. in New York, stretching a recovery in software names that have taken a hit lately. The stock moved between $21.90 and $24.53 earlier, putting Figma’s market cap near $11 billion.

Investors are sifting through software stocks after last week’s pullback, sparked by renewed worries that fresh artificial-intelligence tools could upend some existing products. Retail money poured into BlackRock’s iShares Expanded Tech-Software Sector ETF (IGV), with inflows hitting a record $176 million over a one-month rolling period as of Monday’s close, Vanda Research data showed, according to Reuters.

Despite buyers stepping in on the dip, traders aren’t letting their guard down. Reuters noted the software and services sector has trailed the S&P 500 by close to 24 points over the last three months, and the options market reflects lingering nerves. Implied volatility for IGV over thirty days? Around 41%. That’s not all — short interest remains close to all-time highs, according to the same report.

There’s also a minor research upgrade in play. Figma picked up a bump from Wall Street Zen, which raised its rating to “hold” from “sell” on Sunday, according to MarketBeat. MarketBeat

San Francisco’s Figma, known for its collaborative design tools for websites and apps, went public in July, months after its $20 billion sale to Adobe fell through. The company set its IPO price at $33. Shares rocketed 158% higher on day one, according to Reuters.

Investors will get their next look at Figma’s numbers on Feb. 18. The stock has moved between $19.85 and $142.92 in the last year, per Investing.com.

Tuesday’s session saw choppy action across the board after U.S. retail sales landed flat for December, catching analysts off guard. “It’s really the retail sales data that’s come out below expectations that’s driving some of the weakness,” said Charlie Ripley, vice president of portfolio management at Allianz Investment Management. Reuters

Figma’s quarter hinges on what execs reveal about demand, pricing, and how big clients are spending. Investors are also watching for any mention of competition—especially now, with AI capabilities cropping up in design and productivity software everywhere.

The rebound might not last if earnings or forecasts fall short—or if AI jitters keep spilling out of equities. Morgan Stanley flagged Tuesday that the AI-driven software slide is now creeping into credit markets, and the firm sees “continued price volatility” ahead. A wave of defaults isn’t likely in the near term, but the warning stands. Reuters

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Cadiz, ArriVent BioPharma, Acco Brands join Zacks Strong Sell list for July 21st
    July 21, 2026, 6:12 AM EDT. Cadiz (CDZI), ArriVent BioPharma (AVBP), and Acco Brands (ACCO) were added to the Zacks Rank #5 (Strong Sell) List. Cadiz's earnings estimate tumbled 40%, while ArriVent BioPharma slipped 7.3% and Acco Brands dropped 5.1% in consensus earnings over the past 60 days. These moves mark a significant slide in expected earnings for July 21st.
Merck stock is inches from a 52-week high — and an insider just sold shares
Previous Story

Merck stock is inches from a 52-week high — and an insider just sold shares

AppLovin stock price rises again as UBS trims target and earnings loom
Next Story

AppLovin stock price rises again as UBS trims target and earnings loom

Go toTop